Abstract：
BACKGROUND:The aspirin induced platelet aggregation has been reported to be mediated through the inhibition of platelet prostaglandin synthesis. This compound has also been recently reported to stimulate nitric oxide synthesis in platelets. Since nitric oxide has been reported to produce fibrinogen/fibrinolytic effect, investigation was carried out to determine fibrinolytic effect of in vivo exposure of platelets to aspirin in normal volunteers on the fibrinolysis of the clotted platelet-rich plasma in vitro. The thrombolytic effect of aspirin in situ was also carried out by injecting aspirin solution in the mice with ADP induced formed thrombi in the coronary artery. METHODS AND RESULTS:It was found that the clotted platelet-rich plasma prepared from the volunteers (n = 10, F = 5, M = 5) who ingested 150 mg aspirin, began to undergo spontaneous and progressive fibrinolysis for 200 min at 37 degrees C with the generation of fibrin degradation products in the lysate. No such fibrinolysis could be seen in control experiments. When platelet thrombi were produced in the coronary artery of mice by injecting ADP, and these animals subsequently received intravenous injection of aspirin (4 muM final), they not only survived (P < 0.0001, n = 10) the thrombogenic assault but the lysis of the platelet thrombi was also noted in the post mortem examination. The thrombolytic effect of aspirin was found to be comparable to that of streptokinase in these animals. CONCLUSIONS:Aspirin, through the stimulation of NO synthesis, may produce thrombolysis in vivo.
journal_name
J Thromb Thrombolysisjournal_title
Journal of thrombosis and thrombolysisauthors
Karmohapatra SK,Kahn NN,Sinha AKdoi
10.1007/s11239-007-0023-ysubject
Has Abstractpub_date
2007-10-01 00:00:00pages
123-9issue
2eissn
0929-5305issn
1573-742Xjournal_volume
24pub_type
杂志文章abstract：BACKGROUND:Oxidative stress play an important role triggering platelet/endothelial activation. AGI-1067 is a novel, phenolic antioxidant, and vascular protectant which dose-dependently inhibits PEA biomarkers in vitro. Whether treatment with AGI-1067 alters platelets in vivo is not known. We serially assessed release o...
journal_title：Journal of thrombosis and thrombolysis
pub_type： 杂志文章,多中心研究,随机对照试验
doi：10.1007/s11239-008-0233-y
更新日期：2009-05-01 00:00:00
abstract：:Arterial thrombosis is the leading causes of morbidity and mortality worldwide, whereas venous thrombosis is the most common preventable cause of hospital death. In either case, venous and arterial thrombosis should be considered autonomous entities, with only minor overlaps in terms of risk factors, predisposing cond...
journal_title：Journal of thrombosis and thrombolysis
pub_type： 杂志文章,评审
doi：10.1007/s11239-012-0748-0
更新日期：2012-10-01 00:00:00
abstract：:The REG2 Anticoagulation System consists of pegnivacogin, a subcutaneously administered aptamer factor IXa inhibitor, and its intravenous active control agent, anivamersen. Its effect on thrombin generation is unknown. A prospectively designed thrombin generation study was conducted within the phase 1 ascending dose s...
journal_title：Journal of thrombosis and thrombolysis
pub_type： 杂志文章,随机对照试验
doi：10.1007/s11239-014-1081-6
更新日期：2014-10-01 00:00:00
abstract：:We describe a case of a 67-year-old woman with a history of cerebral infarction and pulmonary embolism that presented with chest pain. Subsequent evaluation resulted in a diagnosis of acute myocardial infarction and occult DVT, and imaging revealed a rare congenital absence of the infra-renal portion of the inferior v...
journal_title：Journal of thrombosis and thrombolysis
pub_type： 杂志文章
doi：10.1007/s11239-005-1380-z
更新日期：2005-04-01 00:00:00
abstract：:Aspirin (acetylsalicylic acid) is one of the main therapeutics in prevention of thrombo-embolic vascular events. Its efficiency is proved in the prevention of cardiovascular events. However, antiplatelet effect of aspirin is not absolute in all patients and some patients experience thrombo-embolic events despite aspir...
journal_title：Journal of thrombosis and thrombolysis
pub_type： 杂志文章,评审
doi：10.1007/s11239-006-9043-2
更新日期：2007-06-01 00:00:00
abstract：:Anticoagulation treatment is effective in preventing both death and recurrence in patients with venous thromboembolism (VTE), but at the same time confers a substantial risk of bleeding complications. The aim of this study was to examine the rate of and predictors for bleeding complications in VTE patients on warfarin...
journal_title：Journal of thrombosis and thrombolysis
pub_type： 杂志文章
doi：10.1007/s11239-015-1305-4
更新日期：2016-02-01 00:00:00
abstract：:Management of intermediate and high risk acute pulmonary embolism (PE) is challenging. The role of multidisciplinary teams for the care of these patients is emerging. Herein, we report our experience with a pulmonary embolism response team (PERT). We conducted a retrospective chart review on all patients admitted to t...
journal_title：Journal of thrombosis and thrombolysis
pub_type： 杂志文章
doi：10.1007/s11239-018-1686-2
更新日期：2018-08-01 00:00:00
abstract：:Throughout the world, herbal medicines are consumed by most of the patients without considering their adverse effects. Many herbal medicines/plant extracts have been reported to interact with the natural blood clotting system. In continuation to this effort, thirty medicinal plant extracts were allowed to interact wit...
journal_title：Journal of thrombosis and thrombolysis
pub_type： 杂志文章
doi：10.1007/s11239-015-1269-4
更新日期：2016-05-01 00:00:00
abstract：:The initial treatment of acute venous thrombosis using low-molecular-weight heparin (LMWH) in the outpatient setting has been shown to be feasible, effective, and safe for selected patients when compared with in-hospital treatment using continuous intravenous heparin. There will always be a significant population of p...
journal_title：Journal of thrombosis and thrombolysis
pub_type： 杂志文章
doi：10.1023/a:1013232803747
更新日期：1998-01-01 00:00:00
abstract：:The current, global situation regarding the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic and its potentially devastating clinical manifestations, i.e. coronavirus disease 2019 (COVID-19), took the world by storm, as millions of people have been infected worldwide and more than 1,600,000 patien...
journal_title：Journal of thrombosis and thrombolysis
pub_type： 杂志文章,评审
doi：10.1007/s11239-020-02374-3
更新日期：2021-01-15 00:00:00
abstract：:The occurrence of an inhibitor against coagulation factor V (FV) is a rare but challenging condition, which may span from asymptomatic laboratory abnormalities to potentially life-threatening bleeding. The onset of FV inhibitors has been associated most frequently in the past with the patients' exposure to topical bov...
journal_title：Journal of thrombosis and thrombolysis
pub_type： 杂志文章,评审
doi：10.1007/s11239-010-0529-6
更新日期：2011-05-01 00:00:00
abstract：:Patients with non-valvular atrial fibrillation who are under chronic oral anticoagulant therapy (OAC) treatment frequently require interruption of OAC treatment. By examining the presence of left atrial/left atrial appendage (LA/LAA) thrombus or dense spontaneous echo contrast (SEC) with transesophageal echocardiograp...
journal_title：Journal of thrombosis and thrombolysis
pub_type： 杂志文章
doi：10.1007/s11239-020-02104-9
更新日期：2020-08-01 00:00:00
abstract：:Argatroban is a parenteral direct thrombin inhibitor labeled for anticoagulation in patients with confirmed or suspected heparin-induced thrombocytopenia in the United States. Currently there are no studies evaluating bleeding risk factors in Intensive Care Unit patients.To determine bleeding risk factors associated w...
journal_title：Journal of thrombosis and thrombolysis
pub_type： 临床试验,杂志文章
doi：10.1007/s11239-012-0758-y
更新日期：2012-11-01 00:00:00
abstract：:Since the reports by Weismann and Tobin in 1958 and Roberts et al. in 1964 called attention to paradoxical thrombosis in patients treated with heparin, the thrombotic aspect of the heparin-induced thrombocytopenia syndrome (HIT) has been emphasized. Yet to this day, the mechanism of thrombosis associated with HIT (HIT...
journal_title：Journal of thrombosis and thrombolysis
pub_type： 杂志文章,评审
doi：10.1023/a:1027372901367
更新日期：2000-11-01 00:00:00
abstract：:Data comparing the patient characteristics, management and outcomes for dabigatran versus warfarin major bleeding in the practice setting are limited. We performed a retrospective single health system study of atrial fibrillation patients with dabigatran or warfarin major bleeding from October 2010 through September 2...
journal_title：Journal of thrombosis and thrombolysis
pub_type： 杂志文章
doi：10.1007/s11239-015-1213-7
更新日期：2015-10-01 00:00:00
abstract：:Anticoagulant plasma concentrations and patient characteristics might affect the benefit-risk balance of therapy. The study objective was to assess the impact of model-predicted rivaroxaban exposure and patient characteristics on outcomes in patients receiving rivaroxaban for venous thromboembolism (VTE) prophylaxis (...
journal_title：Journal of thrombosis and thrombolysis
pub_type： 杂志文章
doi：10.1007/s11239-020-02078-8
更新日期：2020-07-01 00:00:00
abstract：:Argatroban, a hepatically metabolized direct thrombin inhibitor, is approved for anticoagulation in patients with or at risk of heparin-induced thrombocytopenia (HIT) undergoing percutaneous coronary intervention (PCI). We investigated the effect of renal function on argatroban therapy during PCI. From previous argatr...
journal_title：Journal of thrombosis and thrombolysis
pub_type： 杂志文章
doi：10.1007/s11239-009-0357-8
更新日期：2010-01-01 00:00:00
abstract：:Anti-platelet agents or anticoagulants are administered for patients with multiple myeloma (MM) receiving immunomodulatory drugs (IMiDs) to prevent thrombotic events (TEs). However, there is a discrepancy between current guidelines and clinical practice in thromboprophylaxis and the varied incidence of TEs depending o...
journal_title：Journal of thrombosis and thrombolysis
pub_type： 杂志文章
doi：10.1007/s11239-019-01809-w
更新日期：2019-07-01 00:00:00
abstract：:In experimentally induced myocardial ischemia, mild hypothermia (33-35 degrees C) has a robust cardioprotective effect. Tissue plasminogen activator (t-PA) is a profibrinolytic enzyme that is released from the vascular endothelial cells in response to ischemia and other injurious stimuli. t-PA has also been found to h...
journal_title：Journal of thrombosis and thrombolysis
pub_type： 杂志文章
doi：10.1007/s11239-009-0350-2
更新日期：2010-04-01 00:00:00
abstract：:Time to treatment with thrombolytic therapy has been recognized as an important factor in the treatment of patients with acute myocardial infarction: By restoring infarct-related artery patency earlier, clinical outcome is improved. Of the several components of time delay between the onset of pain to opening of the ar...
journal_title：Journal of thrombosis and thrombolysis
pub_type： 杂志文章
doi：10.1007/BF00181669
更新日期：1996-01-01 00:00:00
abstract：BACKGROUND:There are several new strategies proposed to improve the outcome of patients with ST-elevation myocardial infarction (STEMI). One approach is the resurgent use of facilitated percutaneous coronary interventions (PCI). Until recently, deciding whether immediate PCI after combined treatment (facilitated PCI) i...
journal_title：Journal of thrombosis and thrombolysis
pub_type： 杂志文章,随机对照试验
doi：10.1007/s11239-006-5733-z
更新日期：2006-04-01 00:00:00
abstract：:Thrombolytic therapy has become a standard treatment for selected patients with acute myocardial infarction (MI). Various thrombolytic agents have been shown to decrease mortality. However, current thrombolytic agents still suffer significant shortcomings, such as a low optimal reperfusion rate delayed reperfusion. an...
journal_title：Journal of thrombosis and thrombolysis
pub_type： 杂志文章
doi：10.1023/a:1008872031770
更新日期：1998-01-01 00:00:00
abstract：:Fever is a presenting sign in some patients with acute deep venous thrombosis (DVT), but its influence on outcome has not been thoroughly investigated. RIETE is an ongoing, international, observational registry of consecutive patients with symptomatic, objectively confirmed, acute venous thromboembolism. The aim of th...
journal_title：Journal of thrombosis and thrombolysis
pub_type： 临床试验,杂志文章,多中心研究
doi：10.1007/s11239-011-0604-7
更新日期：2011-10-01 00:00:00
abstract：:Hospital acquired venous thromboembolism (VTE) is a major source of morbidity and mortality, yet proven prevention measures are often underutilized. The lack of a validated VTE risk assessment model, difficulty integrating VTE risk assessment and prevention protocols into the routine process of care, and the lack of s...
journal_title：Journal of thrombosis and thrombolysis
pub_type： 杂志文章
doi：10.1007/s11239-009-0405-4
更新日期：2010-02-01 00:00:00
abstract：:The stability of an arterial thrombus, determined by its structure and ability to resist endogenous fibrinolysis, is a major determinant of the extent of infarction that results from coronary or cerebrovascular thrombosis. There is ample evidence from both laboratory and clinical studies to suggest that in addition to...
journal_title：Journal of thrombosis and thrombolysis
pub_type： 杂志文章,评审
doi：10.1007/s11239-018-1641-2
更新日期：2018-05-01 00:00:00
abstract：:The risk benefit decision in providing anticoagulation for patients with brain metastases is amongst the most difficult decisions faced by clinicians. The purpose of our study was to evaluate both the risk of intracerebral hemorrhage (ICH) associated with anticoagulation therapy and the effect of anticoagulation on su...
journal_title：Journal of thrombosis and thrombolysis
pub_type： 杂志文章,meta分析,评审
doi：10.1007/s11239-017-1536-7
更新日期：2017-10-01 00:00:00
abstract：:Direct oral anticoagulants are associated with rates of major bleeding which are not negligible, albeit lower than those associated with vitamin K antagonists. No specific reversal agent for factor Xa (FXa) direct inhibitors is currently available for clinical use. A modified activated human FXa decoy protein, andexan...
journal_title：Journal of thrombosis and thrombolysis
pub_type： 杂志文章,评审
doi：10.1007/s11239-018-1617-2
更新日期：2018-04-01 00:00:00
abstract：:Infarct artery stenting with adjunctive abciximab therapy is widely used treatment for patients with acute myocardial infarction (AMI). However, bleeding complications have been associated with a worse clinical outcome. Randomized trials in elective patients have shown that postprocedural protamine administration is s...
journal_title：Journal of thrombosis and thrombolysis
pub_type： 杂志文章
doi：10.1007/s11239-010-0481-5
更新日期：2010-11-01 00:00:00
abstract：:Early rapid platelet inhibition with abciximab before primary percutaneous coronary intervention (PPCI) for ST-segment elevation myocardial infarction (STEMI) is suggested as beneficial. In previous studies on early abciximab administration clopidogrel was administered in cathlab in low loading dose. We investigated t...
journal_title：Journal of thrombosis and thrombolysis
pub_type： 杂志文章,多中心研究,随机对照试验
doi：10.1007/s11239-010-0461-9
更新日期：2010-10-01 00:00:00
abstract：:Heparin and low-molecular weight heparin (LMWH) are complex, heterogeneous polysaccharides used in the treatment of arterial and venous thrombosis. M118 is a novel LMWH with low polydispersity and pronounced anti-Xa and anti-thrombin (IIa) activity as compared to current LMWHs. To determine if M118 is effective in pre...
journal_title：Journal of thrombosis and thrombolysis
pub_type： 杂志文章
doi：10.1007/s11239-009-0340-4
更新日期：2009-11-01 00:00:00
